Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]

Known as: CERTOLIZUMAB PEGOL 200 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Cimzia], Cimzia 200 MG in 1 ML Prefilled Syringe, Cimzia 200 MG per 1 ML Prefilled Syringe 
 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe
CimziaPrefilled SyringeSodium AcetateSodium Chloride
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Patient Satisfaction with CIMZIA® (Certolizumab Pegol) AutoClicks® in the UK
The CIMZIA® AutoClicks® pre-filled pen (CZP PFP) was developed to overcome barriers to self-injection, by improving self… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 1
Is this relevant?
2018
2018
Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages
Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies… Expand
Is this relevant?
Review
2018
Review
2018
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2017
2017
Certolizumab pegol administration devices: a profile of their use and usability
Certolizumab pegol (Cimzia®), a tumour necrosis factor-α (TNF) antagonist, is an effective and well-tolerated option for the… Expand
Is this relevant?
Review
2017
Review
2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
BACKGROUND Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic… Expand
  • table 1
  • figure 1
  • table 7
  • table 8
  • table 9
Is this relevant?
Review
2014
Review
2014
Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis
Certolizumab pegol (Cimzia®) is a polyethylene glycolylated antigen-binding fragment of a recombinant human monoclonal antibody… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2013
2013
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over… Expand
  • table 1
  • figure 1
Is this relevant?
Review
2013
Review
2013
Certolizumab Pegol
Certolizumab pegol (Cimzia®) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high… Expand
Is this relevant?
Review
2010
Review
2010
2 TNF-α blockers in inflammatory bowel diseases : Practical consensus recommendations and a user ’ s guide
More than seventy years after their initial characterisation, the aetiology of inflammatory bowel diseases remains elusive. A… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE